Research programme - anticancer therapeutics - Escend Pharmaceuticals

Drug Profile

Research programme - anticancer therapeutics - Escend Pharmaceuticals

Alternative Names: ES 3000; ES 4000

Latest Information Update: 30 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ESCEND PHARMACEUTICALS
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Cyclin D inhibitors; Proto oncogene protein c-myc inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Pancreatic cancer

Most Recent Events

  • 28 Dec 2016 ES 3000 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 06 Jun 2016 Research programme - anticancer therapeutics - Escend Pharmaceuticals is available for licensing as of 06 Jun 2016. http://www.escendpharma.com/partners/
  • 02 Jun 2016 ES 3000 receives Orphan Drug status for Chronic myeloid leukaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top